NCT00702377

Brief Summary

To evaluate the safety and efficacy of two artificial tears in dry eye patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
109

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2008

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2008

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

June 19, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 20, 2008

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2008

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

February 10, 2010

Completed
Last Updated

February 2, 2012

Status Verified

January 1, 2012

Enrollment Period

3 months

First QC Date

June 19, 2008

Results QC Date

September 23, 2009

Last Update Submit

January 31, 2012

Conditions

Outcome Measures

Primary Outcomes (3)

  • Tear Break-up Time

    Tear breakup time is the time interval between a blink and the development of a dry spot in the tear film. Less than 10 seconds is abnormal. Dry spot is visible after fluorescein staining when viewed under a slit-lamp.

    Day 0, Day 7, Day 14, Day 28, and Day 42

  • Conjunctival Staining

    Conjunctival staining refers to the appearance of spots on the conjunctiva when dyed with lissamine green stain during an eye examination. Lissamine green temporarily stains the surface of the conjunctiva of the eye. An eye doctor looking at the eye's surface through a slit lamp observes the spots as green spots. Conjunctival staining grading scale is a 6 point scale, with 0 equals no staining (best case) and 6 equals maximum (worst) staining.

    Day 0, Day 7, Day 14, Day 28, Day 42

  • Corneal Staining

    Corneal staining refers to the appearance of corneal abrasions when dyed with fluorescein drops during an eye examination. Fluorescein temporarily stains the surface of the cornea of the eye. An eye doctor looking at the eye's surface through a slit lamp observes the abrasions as brightly-colored spots on an otherwise smooth cornea. Corneal staining grading scale is a 15 point scale, with 0 equals no staining (best case) and 15 equals maximum (worst) staining.

    Day 0, Day 7, Day 14, Day 28, Day 42

Study Arms (2)

SYSTANE Ultra

EXPERIMENTAL

SYSTANE Ultra Lubricant Eye Drops

Other: SYSTANE Ultra

OPTIVE

ACTIVE COMPARATOR

OPTIVE Lubricant Eye Drops

Other: Optive

Interventions

SYSTANE Ultra Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days

SYSTANE Ultra
OptiveOTHER

Optive Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days

OPTIVE

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Documented diagnosis of dry eyes
  • Must not have worn contact lenses for 1 week preceding enrollment

You may not qualify if:

  • Age related

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Contact Call Center for Locations

Fort Worth, Texas, 76134, United States

Location

MeSH Terms

Conditions

Dry Eye Syndromes

Condition Hierarchy (Ancestors)

Lacrimal Apparatus DiseasesEye Diseases

Results Point of Contact

Title
Alcon Clinical
Organization
Alcon Research Ltd

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 19, 2008

First Posted

June 20, 2008

Study Start

June 1, 2008

Primary Completion

September 1, 2008

Study Completion

September 1, 2008

Last Updated

February 2, 2012

Results First Posted

February 10, 2010

Record last verified: 2012-01

Locations